Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): An eastern cooperative oncology group study

Medical Oncology

Volumn 20, Issue 2, 2003, Pages 137-145

  Leaf, Andrea N ^a   Propert, Kathleen ^b   Corcoran, Chris ^c   Catalano, Paul J ^d   Trump, Donald L ^e   Harris, Jules E ^f   Davis, Thomas E ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; Intravenous diethylstilbestrol diphosphate; Metastatic prostate cancer

Indexed keywords

ACID PHOSPHATASE; DOXORUBICIN; ELECTROLYTE; ESTROGEN; FOSFESTROL; HEMOGLOBIN;

ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIETHYLSTILBESTROL; DOXORUBICIN; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0041344318     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:2:137     Document Type: Article

References (20)

1. Jemal, A., et al. (2002). Cancer Statistics CA 52:25.
2. Crawford, E.D., et al. (1989). A controlled trial of leuprolide with and without flutamide in prostate carcinoma. N. Engl. J. Med. 321:419-429.
3. Huggin, C. and Hodges, C.V. (1941). Studies on prostate cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:293-297.
4. Scher, H.I., et al. (1994). Therapeutic Alternatives for Hormone Refractory Prostatic Cancer. Semin. Urol. 10:55-64.
5. Rohlf, P.L. and Flocks, R.H. (1969). Stilphostrol therapy in 100 cases of prostatic carcinoma. J. Iowa Med. Soc. 54:1096.
6. Lee, J.W. (1974). Medical management of advanced prostatic carcinoma with Stilphostrol. Connecticut Med. 38:221.
7. Hawtrey, C.E., et al. (1976). Paraplegia and paraparesis due to prostatic cancer. Use of intravenous diethylstilbestrol diphosphate. Urology 7:598.
8. Susan, L., Roth, R.B. and Atkins, W.E. (1976). Regression of prostatic cancer metastases by high doses of diethylstilbestrol diphosphate. Urology 7:598.
9. Band, P.R., Banerjee, T.K. and Patwardhan, V.C. (1973). High dose diethylstilbestrol diphosphate therapy of prostatic cancer after failure of standard doses of estrogens. Can. Med. Assoc. J. 109:697.
10. Citrin, D.L., Hogan, T.F. and Davis, T.E. (1983). Chemohormonal therapy of metastatic prostate cancer. A pilot study. Cancer 52(3):410-414.
11. Mehta, C.R., Patel, N.R. and Tsiatis, A.A. (1984). Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics 40:819-825.
12. Kaplan, E.L. and Meier, P. (1958). Non parametric estimation of incomplete observations. J. Am. Statist. Assoc. 53:457-481.
13. Mantel, N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163-170.
14. Bailer, J.C., III and Byar, D.P. (1970). Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 26:257-261.
15. Byer, D.P. and Corle, D. (1988). Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urologic Research Group studies. Natl. Cancer. Inst. Monogr. 7:165-170.
16. Robinson, M.R.G. (1988). EORTC Protocol 30805: a phase II trial comparing orchiectomy and cyproterone acetate and low dose Stilbestrol in the management of metastatic carcinoma of the prostate, in Management of Advanced Cancer of the Prostate and Bladder (P.H. Smith and M. Pavone-Macaluso, eds), pp101-110. EORTC Genitourinary Group Monograph 4, Alan R. Liss, New York.
17. Robertson, C.N., et al. (1996). Induction of apoptosis by diethylstilbesrol in hormone insensitive prostate cancer cells. J. Natl. Cancer Inst. 88:908-917.
18. Jaziech, A.R., et al. (1994). Clinical efficacy of diethylstilbestrol treatment in post-orchiectomy progressive prostate cancer. Proc. Am. Assoc. Cancer Res. 35:233.
19. Tannock, I.F., et al. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6):1756-1764.
20. Petrylak, D.P., et al. (1999). Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 17:958-967.